Patents by Inventor Frank Stowasser

Frank Stowasser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9499536
    Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: November 22, 2016
    Assignee: Novartis AG
    Inventors: Nigel Graham Cooke, Frédèric Zecri, Nicolas Soldermann, Romain Wolf, Christina Hebach, Klemens Hoegenauer, Gregory John Hollingworth, Anette Von Matt, Ross Sinclair Strang, Alexander Baxter Smith, Paulo Fernandes Gomes Dos Santos, Nadege Graveleau, Frank Stowasser, Nicola Tufilli
  • Publication number: 20160081934
    Abstract: A process for preparing dry powder formulations of a glycopyrronium salt for inhalation that have good stability. The process involves (a) micronising a glycopyrronium salt together with an anti-adherent agent, and (b) admixing carrier particles to form the dry powder formulation.
    Type: Application
    Filed: December 7, 2015
    Publication date: March 24, 2016
    Applicant: Novartis AG
    Inventors: Barbara Haeberlin, Frank Stowasser, Wolfgang Wirth, Anton Baumberger, Stephen Abel, Sebastian Kaerger, Thomas Kieckbusch
  • Publication number: 20150342951
    Abstract: The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.
    Type: Application
    Filed: December 14, 2012
    Publication date: December 3, 2015
    Applicant: NOVARTIS AG
    Inventors: Nigel Graham COOKE, Paulo Antonio FERNANDES GOMES DOS SANTOS, Pascal FURET, Christina HEBACH, Klemens HOGENAUER, Gregory HOLLINGWORTH, Christoph KALIS, Ian LEWIS, Alexander Baxter SMITH, Nicolas SOLDERMANN, Frederic STAUFFER, Ross STRANG, Frank STOWASSER, Nicola TUFFILLI, Anette VON MATT, Romain WOLF, Frederic ZECRI
  • Publication number: 20150224194
    Abstract: A process for preparing dry powder formulations of a glycopyrronium salt for inhalation that have good stability. The process involves (a) micronising a glycopyrronium salt together with an anti-adherent agent, and (b) admixing carrier particles to form the dry powder formulation.
    Type: Application
    Filed: April 21, 2015
    Publication date: August 13, 2015
    Applicant: Novartis AG
    Inventors: Barbara Haeberlin, Frank Stowasser, Wolfgang Wirth, Anton Baumberger, Stephan Abel, Sebastian Kaerger, Thomas Kieckbusch
  • Patent number: 9006270
    Abstract: The present invention relates to specific solid forms of (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl)-amide, and its solvates. The present invention further relates to processes for preparing said solid forms, pharmaceutical compositions comprising said solid forms, and methods of using said solid forms and pharmaceutical compositions to treat disease.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: April 14, 2015
    Assignee: Novartis AG
    Inventors: Isabelle Sylvie Gallou, Cornelius Gauer, Frank Stowasser
  • Publication number: 20140171470
    Abstract: The present invention relates to specific solid forms of (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl)-amide, and its solvates. The present invention further relates to processes for preparing said solid forms, pharmaceutical compositions comprising said solid forms, and methods of using said solid forms and pharmaceutical compositions to treat disease.
    Type: Application
    Filed: June 19, 2012
    Publication date: June 19, 2014
    Inventors: Isabelle Slyvie Gallou, Cornelius Gauer, Frank Stowasser
  • Publication number: 20140128370
    Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Application
    Filed: January 9, 2014
    Publication date: May 8, 2014
    Applicant: NOVARTIS AG
    Inventors: Nigel Graham COOKE, Frédéric ZECRI, Nicolas SOLDERMANN, Romain WOLF, Christina HEBACH, Klemens HOEGENAUER, Gregory John HOLLINGWORTH, Anette VON MATT, Ross Sinclair STRANG, Alexander Baxter SMITH, Paulo FERNANDES GOMES DOS SANTOS, Nadege GRAVELEAU, Frank STOWASSER, Nicola TUFILLI
  • Patent number: 8653092
    Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: February 18, 2014
    Assignee: Novartis AG
    Inventors: Nigel Graham Cooke, Paulo Fernandes Gomes Dos Santos, Nadege Graveleau, Christina Hebach, Klemens Högenauer, Gregory Hollingworth, Alexander Baxter Smith, Nicolas Soldermann, Frank Stowasser, Ross Strang, Nicola Tufilli, Anette Von Matt, Romain Wolf, Frédéric Zecri
  • Publication number: 20140005123
    Abstract: The invention provides lipid-based pharmaceutical compositions comprising alisporivir.
    Type: Application
    Filed: December 12, 2011
    Publication date: January 2, 2014
    Applicants: DEBIOPHARM S.A., NOVARTIS AG
    Inventors: Elisabete Goncalves, Karin Rapp, Bertrand Sutter, Frank Stowasser, Bjoern Trupp, Sebastian Chabaut, Julien Thorens
  • Publication number: 20130289064
    Abstract: The invention relates to particular crystalline forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile, its hydrates and solvates, its salts and hydrates and solvates of its salts, certain processes for their preparation, pharmaceutical compositions containing these crystalline forms, and their use in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans.
    Type: Application
    Filed: April 4, 2013
    Publication date: October 31, 2013
    Applicant: NOVARTIS AG
    Inventors: Frank Stowasser, Markus Banziger, Sudhakar Devidasrao Garad
  • Patent number: 8563556
    Abstract: Crystalline forms or polymorphs of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one lactic acid salts, as well as to methods of making the same, pharmaceutical compositions comprising the same and methods of treatment using the same.
    Type: Grant
    Filed: March 18, 2009
    Date of Patent: October 22, 2013
    Assignee: Novartis AG
    Inventors: Danielle Giron, Walter Hammerschmidt, Philippe Piechon, Johanne Polasek, Andreas Schreiner, Frank Stowasser
  • Patent number: 8436177
    Abstract: The invention relates to particular crystalline forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile, its hydrates and solvates, its salts and hydrates and solvates of its salts, certain processes for their preparation, pharmaceutical compositions containing these crystalline forms, and their use in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: May 7, 2013
    Assignee: Novartis AG
    Inventors: Frank Stowasser, Markus Bänziger, Sudhakar Devidasrao Garad
  • Patent number: 8178566
    Abstract: The invention relates to new crystal forms of epothilone B.
    Type: Grant
    Filed: August 14, 2007
    Date of Patent: May 15, 2012
    Assignee: Novartis AG
    Inventors: Ernst Küsters, Michael Mutz, Frank Stowasser
  • Publication number: 20120065183
    Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Application
    Filed: July 1, 2011
    Publication date: March 15, 2012
    Applicant: NOVARTIS AG
    Inventors: Nigel Graham COOKE, Paulo FERNANDES GOMES DOS SANTOS, Nadege GRAVELEAU, Christina HEBACH, Klemens HOEGENAUER, Gregory John HOLLINGWORTH, Alexander Baxter SMITH, Nicolas SOLDERMANN, Frank STOWASSER, Ross STRANG, Nicola TUFILLI, Anette VON MATT, Romain WOLF, Frédéric ZECRI
  • Publication number: 20120065174
    Abstract: A process for preparing dry powder formulations of a glycopyrronium salt for inhalation that have good stability. The process involves (a) micronising a glycopyrronium salt together with an anti-adherent agent, and (b) admixing carrier particles to form the dry powder formulation.
    Type: Application
    Filed: October 12, 2011
    Publication date: March 15, 2012
    Inventors: Barbara Haeberlin, Frank Stowasser, Wolfgang Wirth, Anton Baumberger, Stephan Abel, Sebastian Kaerger, Thomas Kieckbusch
  • Patent number: 8119841
    Abstract: This invention relates to crystal forms of aliskiren hemifumarate and various embodiments related thereto, e.g. pharmaceutical preparations, processes for the manufacture of the crystal forms, pharmaceuticals uses and the like. The crystal forms have particularly advantageous properties e.g. they are useful in the manufacture of blood-pressure lowering pharmaceutical preparations and the like.
    Type: Grant
    Filed: November 5, 2007
    Date of Patent: February 21, 2012
    Assignee: Novartis AG
    Inventors: Frank Stowasser, Stephanie Monnier
  • Patent number: 7989494
    Abstract: Polymorphic forms of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide free base and salts thereof are prepared by various processes.
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: August 2, 2011
    Assignee: Novartis AG
    Inventors: Murat Acemoglu, Joginder S. Bajwa, Piotr Karpinski, Dimitris Papoutsakis, Joel Slade, Frank Stowasser
  • Publication number: 20110112308
    Abstract: Salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide are prepared and characterized.
    Type: Application
    Filed: January 14, 2011
    Publication date: May 12, 2011
    Applicant: NOVARTIS AG
    Inventors: Murat Acemoglu, Joginder S. Bajwa, Piotr Karpinski, Dimitris Papoutsakis, Joel Slade, Frank Stowasser
  • Publication number: 20110021536
    Abstract: Crystalline forms or polymorphs of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one lactic acid salts, as well as to methods of making the same, pharmaceutical compositions comprising the same and methods of treatment using the same.
    Type: Application
    Filed: March 18, 2009
    Publication date: January 27, 2011
    Applicant: NORVARTIS AG
    Inventors: Danielle Giron, Walter Hammerschmidt, Philippe Piechon, Johanne Polasek, Andreas Schreiner, Frank Stowasser
  • Publication number: 20100286409
    Abstract: Salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide are prepared and characterized.
    Type: Application
    Filed: May 6, 2010
    Publication date: November 11, 2010
    Applicant: NOVARTIS AG
    Inventors: Murat Acemoglu, Joginder S. Bajwa, Piotr Karpinski, Dimitris Papoutsakis, Joel Slade, Frank Stowasser